The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism

The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism

Aim. To estimate whether optimal antiplatelet therapy can be selected in terms of CYP2C19 polymorphism. Subjects and methods. The prospective randomized trial included 124 patients (93 men and 31 women) who were to undergo percutaneous coronary intervention. They initially received dual antiplatelet...

Full description

Bibliographic Details
Main Authors:	O L Bockeria, Z F Kudzoeva, V A Shvarts, A K Koasari, S A Donakanyan
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2016-05-01
Series:	Терапевтический архив
Subjects:	genetic polymorphism clopidogrel thienopyridines platelets stenting
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/31978/pdf

Similar Items

Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?
by: Berger Peter B
Published: (2000-10-01)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
by: Jan Kiebist, et al.
Published: (2021-09-01)

Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy
by: E F Muslimova, et al.
Published: (2017-05-01)

Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?
by: Rytkin E, et al.
Published: (2017-09-01)

Selective Oxidation of Clopidogrel by Peroxymonosulfate (PMS) and Sodium Halide (NaX) System: An NMR Study
by: Everaldo F. Krake, et al.
Published: (2021-09-01)

Long-term and short-term duration of thienopyridine therapy after coronary stenting in patients with chronic kidney disease a meta-analysis of literature studies
by: Yu Wu, et al.
Published: (2020-05-01)

FEATURES OF PLATELET HEMOSTASIS IN PATIENTS WITH VARIOUS SENSITIVITY TO ANTIPLATELET THERAPY IN STABLE ANGINA PECTORIS AFTER PLANNED PERCUTANEOUS CORONARY INTERVENTION
by: Pronko T. P., et al.
Published: (2017-12-01)

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients
by: J.F.M. Marchini, et al.

Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes
by: Mouhrach I, et al.
Published: (2023-10-01)

SUB-ACUTE STENT THROMBOSIS AND IN-STENT RESTENOSIS ASSOCIATED WITH ANTIPLATELETS CLOPIDOGREL RESISTANCE AND PROTEIN S DEFICIENCY
by: M Zakky Kurniawan, et al.
Published: (2016-11-01)

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
by: Wun Ted, et al.
Published: (2013-02-01)

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV
by: Emanuela Marcantoni, PhD, et al.
Published: (2022-11-01)

Predictors of premature clopidogrel discontinuation within 30 days of successful coronary artery stenting
by: Çayan Cakir, et al.
Published: (2018-01-01)

CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease
by: Sudhir S. Shetkar, et al.
Published: (2014-01-01)

CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS
by: R. Rahmatini, et al.
Published: (2018-04-01)

ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION
by: D. H. Ainetdinova, et al.
Published: (2016-01-01)

Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients
by: Zhang M, et al.
Published: (2020-02-01)

ASSOCIATION BETWEEN SMOKING AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL
by: K. Yu. Lukianets, et al.
Published: (2020-10-01)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
by: Satoshi Niijima, et al.
Published: (2018-03-01)

CYP2C19 Genetic Polymorphism in the East of Iran: Its Association with the Severity and Pattern of Coronary Artery Disease
by: Mahdi Zahedi, et al.
Published: (2019-03-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
by: Amber L. Beitelshees, et al.
Published: (2022-02-01)

Ethyl 13-(4-chlorophenyl)-11-methyl-6-oxo-5-phenyl-8-thia-3,4,5,10-tetraazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,10,12-pentaene-12-carboxylate
by: Elham A. Al-Taifi, et al.
Published: (2016-05-01)

Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study
by: Xiao-Fei Gao, et al.
Published: (2018-05-01)

Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy
by: Abdullah M. Al-Rubaish, et al.
Published: (2020-06-01)

The effectiveness, side effects and acceptability of locally available brand of Clopidogrel (Osvix) as antiplatelet tablet in CABG patients
by: Behzad Imani, et al.
Published: (2014-07-01)

Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance
by: Usman Nawaz, et al.
Published: (2023-11-01)

Effectiveness of Two-Year Versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis After Drug-Eluting Stent Implantation
by: Ali Reza Amirzadegan, et al.
Published: (2012-06-01)

Effectiveness of Two-Year versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis after Drug-Eluting Stent Implantation
by: Hamid Reza Poorhosseini, et al.
Published: (2012-04-01)

Antiplatelet Therapy in a Patient with Coronary Artery Disease and Myelodysplastic Syndrome with Thrombocytopenia
by: Francisco José Fernández-Fernández, et al.
Published: (2017-10-01)

Molecular and metabolic characteristics of changes in the platelet sensitivity to antiplatelet therapy in patients with coronary artery disease before and after coronary artery bypass grafting
by: M. D. Goncharov, et al.
Published: (2021-07-01)

Pharmacodynamic effects of a new fixed-dose clopidogrel–aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial
by: Jin-Sin Koh, et al.
Published: (2017-02-01)

ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2
by: E. V. Gorjacheva, et al.
Published: (2016-01-01)

CYP2C19*1 and CYP2C19*2 Polymorphism in Turkish Patients Being Diagnosed with Stable Coronary Artery Disease and Using Clopidogrel
by: Ramazan Sabırlı, et al.
Published: (2021-03-01)

Cyp2C19*2 Polymorphism Related to Clopidogrel Resistance in Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis
by: Ying Sun, et al.
Published: (2020-12-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention
by: Adam Wiśniewski
Published: (2021-01-01)

Is Preoperative Clopidogrel Resistance a Predictor of Bleeding and Risks in Patients Undergoing Emergency CABG Surgery?
by: Mehmet Kizilay, et al.

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015-12-01)

A Study on the Correlation Between MDR1 Polymorphism and Clopidogrel Resistance in Hui Patients Treated with Percutaneous Coronary Intervention
by: Chen F, et al.
Published: (2021-02-01)

Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE‐ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study
by: Alexander C. Fanaroff, et al.
Published: (2018-02-01)